Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.
University of Kansas School of Pharmacy, Lawrence, Kansas, USA.
Pharmacotherapy. 2022 May;42(5):428-438. doi: 10.1002/phar.2681. Epub 2022 Apr 15.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as "statins" are considered first-line pharmacologic therapy for reducing low-density lipoprotein cholesterol (LDL-C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any pharmacologic therapy, however, they are not without possible adverse effects that can lead to discontinuation, thus leading to a loss of benefit. The most common side effect related to statin therapy impacting compliance is musculoskeletal related, commonly referred to as statin-associated muscle systems (SAMS). While the overall incidence is relatively low, the consequences of nonadherence to statin therapy can have a negative impact on patient care. Therefore, it is important for healthcare providers to understand risk factors, how to diagnose, and how to manage this unfortunate adverse effect in order to optimize care.
3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂，也被称为“他汀类药物”，被认为是降低低密度脂蛋白胆固醇（LDL-C）的一线药物治疗方法。它们已经在各种患者群体中被证明可以降低动脉粥样硬化性心血管疾病（ASCVD）的风险。然而，与任何药物治疗一样，它们并非没有可能的不良反应，这些不良反应可能导致停药，从而失去获益。与他汀类药物治疗相关的最常见的影响依从性的肌肉骨骼相关不良反应通常被称为他汀类药物相关肌肉系统（SAMS）。虽然总体发生率相对较低，但不遵医嘱使用他汀类药物治疗可能会对患者的治疗产生负面影响。因此，医疗保健提供者了解风险因素、如何诊断以及如何管理这种不幸的不良反应以优化治疗非常重要。
